Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
Menveo-Administration in patients older than 55 years; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in an unspecified number of patients who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patients received Menveo. On an unknown date, an unknown time after receiving Menveo, the patients experienced inappropriate age at vaccine administration (Verbatim: Menveo-Administration in patients older than 55 years). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK receipt date: 01-MAY-2025 Pharmacist was concerned because some patients were going to travel abroad, and they had been administered Menveo to people other than 55 years because they need it the vaccine to travel abroad, which led to inappropriate age at vaccine administration. Centers for disease control and prevention (CDC) did not mentioned an specific vaccine brand for this population over 55 years. Follow up was not requested during the call.